American Society of Clinical Oncology Releases Rapid Guideline Recommendation Update for Certain Patients With Hereditary Breast Cancer
June 17, 2021
June 17, 2021
ALEXANDRIA, Virginia, June 17 (TNSJou) -- The American Society of Clinical Oncology issued the following news release:
A new American Society of Clinical Oncology (ASCO) guideline update recommends offering 1 year of adjuvant olaparib to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant chemotherapy and local treatment, including radiation. The recommendations updat . . .
A new American Society of Clinical Oncology (ASCO) guideline update recommends offering 1 year of adjuvant olaparib to patients with high-risk early-stage human epidermal growth factor receptor 2 (HER2)-negative breast cancer and germline BRCA mutations after completion of (neo)adjuvant chemotherapy and local treatment, including radiation. The recommendations updat . . .